Sreelakshmi24’s Blog

where life is all about learning

Archive for the ‘Uncategorized’ Category

leave a comment »

Will be back in few days

Advertisements

Written by sreelakshmi

16 August, 2010 at 10:55 pm

Posted in Uncategorized

Copper can help combat Swine Flu

with 3 comments

Another method to prevent the spread of H1N1 virus. The International Copper Association Ltd. has provided the following details.

Copper touch surfaces have self-sterilizing properties that can prevent the spread of H1N1 virus

 

The recent threat of Swine flu has emerged as the most important health concern in India and has triggered the need to use the most protective and efficient measures to reduce its spread in public places. While we have been advised to be alert, wash our hands regularly, avoid crowded places like cinema halls, shopping complexes, malls etc. International Copper Promotion Council (India) would also like to educate the public about the capability of Copper to combat the spread of the H1N1 virus.

A recent UK study1 has found that copper touch surfaces can significantly reduce the concentration of Influenza A virus on them, raising hopes that it may also be effective against other strains of the virus. The research found that 75 percent of Influenza A are knocked out in 1 hour on a copper surface and almost completely in 6 hours. The work, which was led by Professor Bill Keevil from the University of Southhampton, was presented at the BIT Life Sciences’ 2nd Annual World Summit of Anti-virals in Beijing on July 18. The findings are timely given the current Influenza H1N1 ( more commonly known as Swine Flu ) pandemic currently sweeping the world. But even more common forms of flu are a major global health issue.

The role of surfaces in spreading influenza is now well known. In fact it has been shown that once surfaces are contaminated, fingers can transfer viral particles to up to seven other clean surfaces. Professor Keevil makes it clear that preventing the spread of any strain of Influenza is a very complex process and no one option is likely to be 100 percent successful. “There is no single answer to controlling the spread of pathogenic microorganisms,” Prof Keevil
et al state in the paper. The current study shows that copper surfaces may contribute to the number of control barriers able to reduce transmission of the virus.

H1N1 virus appears to be transmitted the same way that seasonal flu spreads. Flu viruses are spread mainly from person to person through coughing or sneezing. Sometimes people may become infected by touching something with flu viruses on it and then touching their mouth or nose.

 

Last year, the U.S. Environmental Protection Agency (EPA) approved the registration of antimicrobial Copper alloys, with Public Health Claims acknowledging that Copper, Brass and Bronze are capable of killing harmful, potentially deadly bacteria. Copper and Copper alloy surfaces kill greater than 99.9% of (specific) bacteria within two hours, and continue to kill more than 99% of (these) bacteria even after repeated contamination. Therefore, it has been recognized that the use of Copper touch surfaces in hospitals, educational institutions, public buildings, public transport and food preparation areas can reduce the spread of harmful infections.

Copper and its alloys are available in a variety of forms like door handles, grab rails and bathroom fixtures etc. which are regular touch surfaces and can work to demonstrate reduced build-up and transfer of infectious pathogens.

Mr. Ajit Advani, Dy. Regional Director Asia, International Copper Association Ltd. & CEO, International Copper Promotion Council (India) said: “In India, we have known about the protective properties of Copper since the vedic ages. This has now been corroborated by modern Science. Use of this wonder metal in public touch surfaces can go a long way in reducing the spread of infections such as Influenza”.

Dr. Anu Kant Mital, Associate Professor & Head of Department, Rajiv Gandhi Medical College, and President Indian Association of Biological Psychiatry said, “Touch surfaces such as Taps, Door handles, Railings etc. are the first portals of entry for any infection into the pool of becoming The Epidemic. This is especially significant in our country as we have a large population and the numbers that would be involved in the touch and spread model are mind boggling. In this context The Anti-Microbial or more descriptively put Self Sterilizing (self cleansing) properties of COPPER, established scientifically and accepted by the authorities world over now,( that we have known since eons) would be heaven sent. All the surfaces that are touched by thousands daily, if made of copper would not be aiding the spread of any infection, especially like the H1N1.”

Note:
The use of a Copper alloy surface is a supplement to and not a substitute for standard infection control practices; users must continue to follow all current infection control (hygienic) practices including those practices related to cleaning and disinfection of environmental surfaces.


 

Written by sreelakshmi

23 August, 2009 at 8:24 am

Busting Swine Flu Myths- Dr. Mukesh Batra

leave a comment »

The death toll thanks to the H1N1 viral flu is increasing. Famous homeopath Dr. Mukesh Batra talks about homeopathy treatment for the disease.

 

Swine flu is creating panic all over the world and there are many myths, misconceptions, and rumours going around that are only making matters worse. Under these circumstances, it is therefore important for people to stay calm and composed so that they act responsibly and appropriately. Many think that a vaccine for swine flu will do the trick and protect against the virus. However, the truth is that no one can be sure about this because viruses are known to mutate easily, thereby rendering such a vaccine useless. Some scientists are even afraid about the possibility of another mutation taking place when the swine flu virus H1N1 comes into contact with the Bird flu virus H5N1. This again is just a remote possibility and not a certain outcome. People were under the impression that just because bird flu spread by eating infected poultry, swine flu could spread by eating infected pork. It is now confirmed by the Centres for Disease Control and Prevention that that it is safe to eat hygienically cooked pork. The amount of protection offered by masks is also not very clear. Although they could definitely reduce the likelihood of contracting the infection, they cannot really assure complete protection. Thus, it is safer to avoid coming in close proximity with patients with flu-like symptoms. Another trend is closing down schools, colleges, or other institutions to prevent the spread of the disease and advising people to stay at home. This, however, is not a feasible option and is hence not recommended. The biggest solace is the fact that the infection seems to be moderate in intensity in majority of the patients with only a small section, especially those with underlying pathologies or poor immunity, succumbing to the disease.

 
 

With so much of uncertainty around, giving Homeopathy an opportunity to prevent or treat the disease makes perfect sense for two reasons. Firstly, disease causing organisms can never get resistant to homeopathic remedies because homeopathic medicines do not target the causative organisms directly. They stimulate the body’s defences instead to attack and overpower the invaders. Secondly, being free of adverse side-effects, homeopathic medicines can be safely administered in infants, pregnant women, and the aged. Knowing that conventional medicines are strong, aggressive, and at times even invasive, it goes without saying then that Homeopathy should ideally be the first line of treatment. As homeopathic medicines themselves behave like vaccines by modulating the immunity of an individual, these should be immediately employed in the meanwhile before a successful swine flu vaccine actually enters the market. Antiviral preparations should be used only if the desired curative response is not seen in spite of homeopathic treatment. In acute illnesses like flu, patients usually respond very fast to Homeopathy; and therefore, a homeopath can easily tell within a day or two following the commencement of treatment whether the disease is responding positively, progressing, or heading towards complications. All said and done, one thing is for sure. In pandemics like these, the patient has to be closely monitored by the treating physician, irrespective of his or her specialization, so as to ensure that an unnecessary delay in treatment never occurs. In fact, an approach in which Homeopathy is boldly backed by conventional medicine, where the latter is used wisely and not indiscriminately, seems to be the way to go!

 
 


 
 

What does homeopathy have to say about swine flu?

The fact that diseases are not caused by the mere presence of disease-causing organisms in the internal or external environment, but rather due to the weakening of the body’s defence mechanisms, has always been recognised by homeopathy. Therefore, while the use of antibiotic and antiviral preparations can be rendered useless if the organism gets resistant to them by undergoing a mutation, this can never happen with homeopathic remedies because unlike medicines from other medical systems that target only the disease-causing germs or aim to offer symptomatic relief, homeopathic medicines act upon the immune system and restorative energies of the body so that it heals itself. Other systems simply suppress symptoms and treat the body in parts, whereas homeopathy recognises the body as a unified whole and confronts the problem from deep within. Thus, swine flu for homeopathy is just another type of flu that can be treated by stimulating the immune system to overpower the virus. 

 
 

Which homeopathic medicines should be taken to treat the disease?

In the past, various flu epidemics such as the Spanish flu and bird flu have been successfully treated and prevented by homeopathic remedies like Gelsemium, Bryonia, Influenzinum, and Oscillococcinum. These could certainly be of value even in the prevention or treatment of swine flu. In homeopathy, remedy selection depends upon the disease manifestation and not merely the diagnosis; therefore, the prescription varies from case to case. During epidemics, however, since the disease symptoms are more or less similar in most of the cases, a single remedy may help to treat the disease. Such a homeopathic medicine is termed the ‘genus epidemicus.’ The theory of vaccination borrows from the isopathic concept of homeopathy where medicines prepared from the causative organisms (isodes) or affected tissues themselves (nosodes) are used to treat the same or similar diseases in the same or other patients. Preparing an isode or nosode of the swine flu virus is another option that homeopathic pharmaceutical companies could consider in the prophylaxis or therapeutics of the disease. 

 
 

What precautions should be taken by the affected person?

The affected person should avoid meeting people till the disease runs its course. Covering the nose and mouth with a handkerchief when coughing or sneezing is important to prevent spreading the virus to others. Wearing a mask will also help for the same purpose. The patient should not share his or her clothes, towels, soap, and other personal objects with others and must not eat or drink from the same utensils as others. This is necessary because the virus is usually present in all the secretions of the body such as saliva, sweat, phlegm, urine, and stool. As in all viral infections, the patient should drink a lot of fluids to stay well hydrated. Eating nutritious food and resting adequately is a must to help the body to recover as well as to prevent complications or secondary infections. According to the Centres for Disease Control and Prevention, majority of the cases that require hospitalization or succumb to the disease are those people who concurrently have underlying pathologies like diabetes, cardiovascular disease, asthma, obesity, or extremely poor immunity. Therefore, such patients should be closely monitored.

 
 

Can homeopathic medicines cure the disease?

An acute illness like flu always heals by crisis or lysis, i.e., it runs its natural course leading to recovery, complications, or death. Thus, in such cases, it is the body that cures itself and homeopathic remedies facilitate this curative process. The logic behind the treatment is not just to relieve symptoms. It is to cut short the natural course of the disease or to allow it to run its course uneventfully without any complications or mortality. Viral infections further drop the immunity of an individual so as to lead to secondary bacterial infections or can even evoke abnormal responses from the body to give rise to autoimmune diseases or pave the way for the development of some cancer. Since homeopathic remedies basically correct the imbalances of the immune system, such problems can largely be prevented.  

 
 

Is homeopathy the preferred choice of medication?

Homeopathic remedies, being infinitesimally small doses, are absolutely safe. They are palatable, non-invasive, and do not produce any deleterious side-effects even when taken for prolonged periods of time. Natural and harmless, they can be administered to infants or the aged without any risk of any adverse reactions. Another major advantage is that homeopathic medicines are cost-effective too as thousands of serial dilutions can be created out of a single drop of the source material. homeopathic remedies are curative as well as preventive; besides, a single remedy can treat symptoms related to multiple organs or systems and also offer protection against complications. There is no question of the causative organisms getting resistant to homeopathic drugs as the latter have no direct action on the former. Considering all these plus points, Homeopathy definitely should be the preferred choice of medication

  

Written by sreelakshmi

23 August, 2009 at 8:06 am

Bajaj Allianz to sponsor safety boat for the Nehru Trophy Boat Race 2009

leave a comment »

 

For the first time in the history of the most popular boat races in Kerala, a safety boat is to be introduced by a private company. This safety boat which contains all the necessary safety equipments like life jackets, first aid kits, etc. will move alongside the race participants and will be sponsored by Bajaj Allianz.

 

Ms. Mini Anthony
Collector, Alappuzha, said, “In the 57 years history of this race, this is the first time that a private company like Bajaj Allianz has taken this noble initiative to supplement the safety efforts towards the race. Though all the participants are expert swimmers and are as capable as a duck takes to water, we decided to have this safety measure as a matter of abundant caution to ensure a safe passage and administer instant medical aid in case of a mishap. ”

 

The safety boat is a motorized boat and is handled by an expert who steers ahead of the teams in a separate lane. Being motorized it can reach at any point of disaster site instantly. It is equipped with life jackets, first aid kits, communication aid which helps to be in touch with the control site and other emergency centres like hospitals, nursing homes, etc..They are also well adapted in disaster management control measures like CPRs, handle any trauma related mishaps etc..

 

Speaking on the association to sponsor the safety boat, Akshay Mehrotra, Head- Marketing, Bajaj Allianz
Life Insurance said, “The core competence of Bajaj Allianz as a leading insurance provider is to help our customers and ensuring a carefree living i.e. jiyo befikar. The idea of a safety boat in the most popular boat race fits very well in extending this proposition. ”

 

As the official partner for the event, Bajaj Allianz would work closely with the organizers to ensure safety messages to ensure a safe and peaceful event.


 

Written by sreelakshmi

9 August, 2009 at 9:59 pm

Posted in Uncategorized

NOW, ONSCREEN SMOKING IS MIMICKED ONSCREEN

leave a comment »

 
 

Recent telecast of TV series depicts peer pressure for smoking among minors; influence attributed to filmstars’ smoking in movies

Onscreen smoking has been repeatedly proven to influence smoking behaviour among adolescents. In a new development, the influence of onscreen smoking on the big screen has been replicated on the small screen as well. In a telecast of a highly viewed TV series on the evening of 28th July, one particular scene actually depicted a minor influencing another minor to initiate smoking, citing examples of film stars doing so in the movies as a mark of style and care-free living. Although actual smoking has not been depicted in the scene portrayed, there was a pack shot of the cigarette brand which itself is a clear reflection and acceptance of the fact that onscreen smoking does have an influence on adolescent smoking behaviour. The serial in question has already created a controversy due to its subject matter in last few weeks.

 
 

Speaking on the issue, Dr. P.C. Gupta, Director, Healis Sekhsaria Institute for Public Health, said, “It has been proven through numerous studies and research conducted across multiple geographies that onscreen smoking clearly does influence the youth – especially adolescents to smoke whether it is portrayed positively or negatively to initiate smoking. This issue has been very conveniently put on the backburner even by the Union Health Minister through his recent comments of onscreen smoking counting as ‘artistic freedom’. But the truth is that in a country such as ours, there is a large population of youth who are exposed everyday to movies and television series, and it is these adolescents who stand to be encouraged by depiction of smoking on screen.”      

 
 

In a recent study conducted in the US by the American Academy of Pediatrics to determine exposure to movie smoking in relation to smoking initiation among US adolescents, prevalence of smoking was seen to be about 2% among those with the lowest exposure to smoking in movies, steadily going up to almost 30% among those with highest exposure. This study clearly demonstrates the association between onscreen smoking exposure reflecting on smoking initiation among adolescents. In fact, the study further suggests that exposure to movie smoking is a primary independent risk factor, accounting for smoking initiation in more than one-third of US adolescents, 10 to 14 years of age.

 
 

Another point to be noted regarding the scene depicted on the TV show is the content that is used to portray the negative character influencing the positive character to smoke. The dialogues used in the scene speak of how it is acceptable to smoke, as onscreen actors also smoke to relieve their tension and it adds to their style. Although this is not a clear depiction of smoking on screen, it is still a potentially powerful motivator for adolescents viewing the show to believe that it is actually acceptable to smoke, and subsequently initiating smoking without any knowledge of the health risks involved. It should also be realized that the pack shot is in effect advertisement of a brand. This possibility is justified by further research – through another survey conducted among 6000+ US adolescents, it was observed that 13.7% of the respondents actually started smoking after being exposed to positive characters smoking in a random sample of movies.

 
 

In light of so many such conclusive research reports, it is definitely essential for the authorities to recognize the fact that onscreen smoking and adolescent exposure to the same have a significant impact on smoking behaviour – and subsequently the numerous health risks that arise from such exposure. These research reports further highlight the need for strict government action to curb the depiction of onscreen smoking – be it in the movies or on television.

  

Written by sreelakshmi

30 July, 2009 at 11:03 pm

Posted in Uncategorized

Lupin Net Profit up by 25 % in Q1, FY 2009-10

leave a comment »

Outpacing and Outperforming Markets globally

 
 

Leading transnational pharmaceutical major Lupin, reported an outstanding performance for the first quarter – FY 2009-10. These audited results were taken on record by the Board of Directors at a meeting held in Mumbai today.

 
 

Key Financial & Performance Highlights

 
 

  • Net sales grew by 26% to Rs. 10,856 million for Q1 FY 2009-10, from Rs. 8,623 million (Q1 FY 08-09)

     
     

  • Net profits for Q1 FY 2009-10 grew by 25% to Rs. 1401 million as compared to Rs 1120 Mn. (Q1 FY 2008-09)

 
 

  • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) grew by 25% to Rs. 2152 Mn. for Q1, FY 2009-10, from Rs. 1728 Mn. (Q1 FY 08-09). Margins remain consistent at 20%

 
 

Commenting on Lupin’s performanceDr. Kamal K Sharma, Managing Director, Lupin Limited, said, “On the back of our strong performance over the last 13 quarters, built on innovative market strategies and also our consistent focus on targeting niche therapy segments and developing difficult-to-make products,Lupin today, has the unique distinction of being the fastest growing company amongst  the Top 10 players in the Generics markets of U.S, Japan, India and South Africa and it also continues to outpace and outperform the Industry therein. This quarter, in keeping with our consistent track record, Lupin has clocked in an impressive and steady rise of 26 % in the Top-line and 25 % in the bottom-line. We now aim to consolidate on the gains made over the past three years to create the foundation to maintain momentum and scale higher orbits of growth.”

 
 

Balance Sheet Highlights

 
 

  • Net Working capital reduced by Rs. 610 Mn. to Rs. 10,778 Mn. as on 30th June 09 against Rs. 11,388 Mn. as on 31st March 09, despite a 26% increase in net sales reflecting optimization on the working capital front.
  • Capital Expenditure during the Quarter – Rs. 1525 Mn.
  • Debt Equity Ratio improved to 0.47 as on 30th June 2009 from 0.62 as on 31st March 2009.
  • FCCB conversions happening at a faster pace.

 
 

Profit & Loss Highlights

  • Material cost remained constant at 43% of Net Sales at Rs. 4676 Mn. during the quarter as against Rs. 3720 Mn. (Q1 2008-09).
  • Personnel cost remained constant at 12% of Net Sales at Rs. 1315 Mn. during the quarter as against Rs. 1014 Mn. (Q1 2008-09).
  • Selling, General and Administrative costs reduced by 0.5% to 26.9% of Net Sales at Rs. 2923 Mn. during the quarter as against Rs. 2363 Mn. (Q1 2008-09).
  • Taxation reduced to 20% in Q1 2009-10 against 22% in Q1 2008-09 amounting to Rs. 364 Mn. against Rs. 313 Mn.
  • Revenue Expenditure on R&D amounts to Rs. 685 Mn., 6.3% to Net sales as against Rs. 477 Mn., 5.5% to Net Sales (Q1 FY 08-09)

 
 

  
 

 
 

Operational Highlights

 
 

  • Advanced markets Formulation sales (including US, Europe & Japan) increased 41 % to Rs. 4858 Mn. during Q1, FY 2009-10, from Rs. 3450 Mn. (Q1 FY 08-09). It contributed 45 % of the Net Sales for the Quarter.

     
     

  • Formulation Sales  in US and EU grew by 40 % to Rs 3551 million, Q1, FY 2009-10, from Rs. 2530 Mn., (Q1, FY 2008-09).

     
     

  • Lupin remains the fastest growing generic players in the US by prescriptions and the 9th largest in terms of overall prescription base

     
     

  • Ranks in the Top 3, in 18 out of 22 generic products in the US market with market leadership (No 1) in 8 of these products. (IMS)

     
     

  • Overall EU Formulation Sales including Hormosan grew by 101% to Rs. 413 Mn., during Q1, FY 2009-10, up from Rs. 206 Mn. (Q1, FY 2008-09)

 
 

  • Lupin’s Japanese subsidiary, Kyowa contributed 12 % of the overall revenues. Recording an Impressive Growth of 42 % to Rs. 1307 million, Q1, FY 2009-10 from Rs. 920 Mn. (Q1, FY 2008-09)

     
     

  • Net Sales of India Region Formulations grew by 22% to Rs. 3444 million for Q1, FY 2009-10 as compared to Rs. 2834 million (Q1 FY 2008-09).

     
     

  • South Africa sales grew to Rs. 301 Mn. during Q1, FY 2009-10 representing a growth of over 40% over Q1 2008-09.

 
 

Operational Summary

 
 

USA & Europe

 
 

Lupin continues to maintain its upward growth momentum in the US & European Markets with it contributing a healthy 33% to total revenues. Sales (Formulations) for US & Europe grew by 40 % to Rs. 3551 Mn. from Rs. 2530 Mn. (Q1 FY 08-09).

 
 

USA

 
 

Quarter 1, also saw Lupin expand its Brand Business in U.S with the acquisition of the worldwide rights for the intra-nasal steroid (INS) product, AllerNaze™ (triamcinolone acetonide, USP) Nasal Spray, 50mcg from Collegium Pharmaceutical, Inc. The INS market generated $ 2.5 Billion in annual sales in United States alone (IMS data).

 
 

Lupin is in the Top 3 in 18 out of 22 of its generic products in the market, out of which 8 are market leaders (IMS).

 
 

 
 

USFDA Approvals

 
 

Lupin received the final approvals for two of the Company’s Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (USFDA). The approvals received were for –

 
 

  • Levofloxacin tablets 250 mg, 500 mg and 750 mg dosage strengths.

     
     

  • and Ethambutol Hydrochloride Tablets USP, 100 mg and 400 mg.

 
 

 
 

The company now has a total of 91 ANDA filings, of which 35 have been approved by the USFDA.

 
 

Europe:

 
 

The Formulations revenues from EU Markets reported a growth of 101 % recording sales of Rs 413 Mn. during Q1, 2009-10 as against Rs. 206 Mn. (Q1, FY 2008-09)

 
 

 
 

 
 

 
 

 
 

Japan

 
 

Lupin continues to outpace the generics market in Japan through its subsidiary, Kyowa. In Q1 09-10, Kyowa registered a phenomenal growth of 42 % to record Net Sales at Rs. 1307 Mn., as against Rs. 920 Mn., Q1 2008-09. It contributed 12% to Lupin’s overall revenues.

 
 

Indian Region Formulation

 
 

India forms a very important part of Lupin overall growth, and contributed 32 % to its overall revenues during Q1, FY 2009-10. The India Formulations grew by 22 % to clock in revenues of 3444 Mn. during Q1, FY 2009-10, as compared to Rs. 2834 Mn. for Q1 2008-09. Branded Formulation sales grew by 24% from Rs. 2336 Mn. to Rs. 2896 Mn.

 
 

South Africa

 
 

Lupin’s South African Business – Pharma Dynamics clocked in revenues of 301 Mn. during Q1, FY 2009-10 representing a growth rate of over 40%.

 
 

API

 
 

API (Net) sales (Including Novodigm) were at Rs 1752 Mn. for Q1 FY 2009-10 versus Rs. 1966 Mn. for Q1 Fy 2008-09. The emphasis as in the past was on value added formulation business.

 
 

R&D

Revenue Expenditure on R&D amounts to Rs. 685 Mn., 6.3% to Net sales as against Rs. 477 Mn., 5.5% to Net Sales in Q1 FY 08-09. Lupin’s cumulative ANDA filings with the USFDA rose to 91 with the company having received 35 approvals to date. Cumulative Filings with the European regulatory authorities stands at 53 with the company having received 22 approvals to date.

Written by sreelakshmi

30 July, 2009 at 10:59 pm

Posted in Uncategorized

Piramal Healthcare Reports Q1 FY2010 Results

leave a comment »

Piramal Healthcare Limited (PHL) (NSE: PIRHEALTH, BSE: 500302) today reported first

quarter (Q1) results for FY2010.

Total Operating Income on consolidated basis for the quarter ended 30 June 2009 was up by 16.0% to Rs. 8.2

billion over Q1FY2009. Operating Profit increased by 34.0% to Rs. 1.6 billion, Operating Profit Margin for the

quarter was up to 19.5% in Q1FY2010 from 16.9% in Q1FY2009. Net Profit for the quarter was up by 25.0% to

Rs. 851.0 million. Earnings Per Share (EPS) for the quarter was up by 24.8% to Rs. 4.1 as compared to Rs. 3.3

for Q1FY2009.

During the quarter, the Healthcare Solutions (Domestic Formulations) division reported strong growth of 25.6% as

compared to industry growth rate of 13.3% (Source: ORG IMS) and had revenue of Rs. 4.4 billion. PHL grew

particularly well in the Respiratory, Dermatology, Anti-diabetic and Anti-infective therapy areas. During the

quarter, the company has launched 9 new products. On a MAT basis, PHL is the number 1 company for new

product introductions. (Source: ORG IMS)

The Company’s Pharma Solutions (Custom Manufacturing) sales was Rs. 1.9 billion during Q1FY2010 as

compared to Rs. 2.3 billion for Q1FY2009. Pharma Solutions revenues from facilities in India grew during

Q1FY2010 by 2.1% to Rs. 601.5 million. The Company continues to adhere to highest standards of quality in

manufacturing. During the quarter, the Company’s manufacturing sites at Pithampur in India and Morpeth in UK

were inspected by the USFDA and have been cleared without any 483s. The Company’s manufacturing facility at

Pithampur has qualified for Frost & Sullivan’s “Asia Manufacturing Excellence Award 2009” in the Platinum

category.

Global Critical Care business grew by 352.7% to Rs. 728.8 million. The operations of Minrad International, a

company which was acquired in Q4FY09 has been integrated completely with Piramal Healthcare. Minrad has

registered sales of US $ 9.6 million for the quarter as compared US $ 23.0 million for full year of 2008.

Written by sreelakshmi

23 July, 2009 at 10:31 pm

Posted in Uncategorized